DTP Organization

DTP Organization

Enlarge

Office of the Associate Director

The Office of the Associate Director provides planning, implementation and oversight for all DTP activities, including participation in the NCI Experimental Therapeutics (NExT).

Preclinical Therapeutics Grants Branch

Preclinical Therapeutics Grants Branch resides in a unique situation in relation to the extramural grant community and DTP’s drug discovery and development activities. Through management of a large grant and cooperative agreement portfolio, PTGB staff maintains extensive interactions with the external research community and can provide advice to foster DTP’s drug discovery mandate.
 

Molecular Pharmacology Branch

The Molecular Pharmacology Branch runs the classical NCI60 cell line screen as a service available to the global cancer community where investigators can submit compounds and biologics for testing in this well validated resource. MPB can also provide investigators with frozen pellets, DNA and RNA from the NCI60 cell lines for their specific studies.
 

Biological Testing Branch

The Biological Testing Branch operates at Frederick (NCI-Frederick), providing budgetary oversight and technical direction for an extensive contractual effort designed to discover chemotherapeutic agents for cancer, including in vivo study model development and screening, distribution of experimental animal and human tumor cell lines, production and distribution of genetically and biologically defined rodents.

Toxicology and Pharmacology Branch

The primary responsibility of the Toxicology and Pharmacology Branch is to obtain the toxicology and pharmacology data necessary for NCI to file an Investigational New Drug (IND) application with the FDA in order to conduct Phase I clinical trials of new oncolytic agents in humans.

Drug Synthesis and Chemistry Branch

NCI's Drug Synthesis and Chemistry Branch provides worldwide scientific liaison activities with universities and industries to stimulate the submission of a wide variety of synthetic compounds, and pure natural products for in vitro anti-cancer screening; management of the storage, inventory, documentation, synthesis, acquisition and distribution of chemical samples for research purposes to NIH and external investigators.
 

Natural Products Branch

The Natural Products Branch is responsible for the acquisition and distribution of crude natural product materials from terrestrial and marine environments worldwide, and oversights the operations of the Natural Products Repository and the Natural Products Extraction Laboratory.
 

Biological Resources Branch

The Biological Resources Branch provides oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick), which produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. BRB also oversees a biological Preclinical Repository for the distribution of cytokines, monoclonal antibodies, and a grant program in the area of biological agents, immunological concepts, and animal models for cancer treatment.

Pharmaceutical Resources Branch

The Pharmaceutical Resources Branch provides the clinical research community with high-quality and well-characterized chemical substances and drug products. Whenever possible, USP/NF grade excipients with a proven track record for consistency and safety are used. The clinical supplies PRB provides are guaranteed to meet or exceed FDA accepted potency and purity requirements while in use.

Information Technology Branch

The Information Technology Branch manages the chemical and biological databases to support DTP’s ongoing research efforts. ITB employs state-of-art software and hardware facilities to provide support for DTP and engages in collaborative research to promote further implementation of information technology within the branch.
 

ImmunoOncology Branch

The ImmunoOncology Branch initiates and coordinates various projects and initiatives to advance immunotherapy research. This includes fostering collaborations with academia and industry, providing guidance on drug development processes, identifying promising immunotherapeutic agents, reviewing grant proposals, and collaborating with the Cancer Therapy Evaluation Program (CTEP) to optimize clinical trials and drug combinations.